share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K：外国发行人报告
美股SEC公告 ·  07/01 06:24
Moomoo AI 已提取核心信息
Alterity Therapeutics Limited, a development stage enterprise, has announced the issuance of unquoted equity securities under an employee incentive scheme. The announcement, dated June 28, 2024, detailed the issue of three new classes of options not intended to be quoted on the ASX. These options, with expiry dates ranging from March 13 to March 21, 2029, and exercise prices between AUD 0.004 and USD 0.003, were issued on June 27, 2024. A total of 209 million options were distributed across the three classes, with the largest single issuance of 120 million options granted to David Stamler, a key management personnel. The options, upon exercise, will convert into ordinary fully paid shares of Alterity Therapeutics. The company confirmed that the securities were issued under an exception in Listing Rule 7.2, negating the need for security holder approval.
Alterity Therapeutics Limited, a development stage enterprise, has announced the issuance of unquoted equity securities under an employee incentive scheme. The announcement, dated June 28, 2024, detailed the issue of three new classes of options not intended to be quoted on the ASX. These options, with expiry dates ranging from March 13 to March 21, 2029, and exercise prices between AUD 0.004 and USD 0.003, were issued on June 27, 2024. A total of 209 million options were distributed across the three classes, with the largest single issuance of 120 million options granted to David Stamler, a key management personnel. The options, upon exercise, will convert into ordinary fully paid shares of Alterity Therapeutics. The company confirmed that the securities were issued under an exception in Listing Rule 7.2, negating the need for security holder approval.
Alterity Therapeutics Limited宣布发行非上市股权证券作为员工激励计划的一部分，该公司是一家处于开发阶段的企业。公告日期为2024年6月28日，详细说明了发行三种新期权的问题，这些期权不打算在ASX上公开报价。这些期权的到期日从2029年3月13日到3月21日不等，行权价格介于AUD 0.004和美元指数0.003之间，于2024年6月27日发行。总共分配了3个类别的2.09亿份期权，其中最大的单笔发行量为1.2亿份，授予了关键管理人员David Stamler。该期权在行权时将转换为Alterity Therapeutics的普通全额支付股票。该公司证实，该证券是根据上市规则7.2的例外发行的，因此无需获得证券持有人的批准。
Alterity Therapeutics Limited宣布发行非上市股权证券作为员工激励计划的一部分，该公司是一家处于开发阶段的企业。公告日期为2024年6月28日，详细说明了发行三种新期权的问题，这些期权不打算在ASX上公开报价。这些期权的到期日从2029年3月13日到3月21日不等，行权价格介于AUD 0.004和美元指数0.003之间，于2024年6月27日发行。总共分配了3个类别的2.09亿份期权，其中最大的单笔发行量为1.2亿份，授予了关键管理人员David Stamler。该期权在行权时将转换为Alterity Therapeutics的普通全额支付股票。该公司证实，该证券是根据上市规则7.2的例外发行的，因此无需获得证券持有人的批准。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息